ALT
Price
$4.17
Change
+$0.11 (+2.72%)
Updated
Jul 22, 03:47 PM (EDT)
Capitalization
328.48M
16 days until earnings call
OVID
Price
$0.64
Change
+$0.03 (+4.92%)
Updated
Jul 22, 04:29 PM (EDT)
Capitalization
43.05M
27 days until earnings call
Interact to see
Advertisement

ALT vs OVID

Header iconALT vs OVID Comparison
Open Charts ALT vs OVIDBanner chart's image
Altimmune
Price$4.17
Change+$0.11 (+2.72%)
Volume$300
Capitalization328.48M
Ovid Therapeutics
Price$0.64
Change+$0.03 (+4.92%)
Volume$2.84K
Capitalization43.05M
ALT vs OVID Comparison Chart in %
Loading...
ALT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
OVID
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ALT vs. OVID commentary
Jul 22, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ALT is a Hold and OVID is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 22, 2025
Stock price -- (ALT: $4.05 vs. OVID: $0.61)
Brand notoriety: ALT and OVID are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ALT: 43% vs. OVID: 152%
Market capitalization -- ALT: $328.48M vs. OVID: $43.05M
ALT [@Biotechnology] is valued at $328.48M. OVID’s [@Biotechnology] market capitalization is $43.05M. The market cap for tickers in the [@Biotechnology] industry ranges from $286.69B to $0. The average market capitalization across the [@Biotechnology] industry is $2.43B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ALT’s FA Score shows that 0 FA rating(s) are green whileOVID’s FA Score has 0 green FA rating(s).

  • ALT’s FA Score: 0 green, 5 red.
  • OVID’s FA Score: 0 green, 5 red.
According to our system of comparison, OVID is a better buy in the long-term than ALT.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ALT’s TA Score shows that 5 TA indicator(s) are bullish while OVID’s TA Score has 6 bullish TA indicator(s).

  • ALT’s TA Score: 5 bullish, 5 bearish.
  • OVID’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, OVID is a better buy in the short-term than ALT.

Price Growth

ALT (@Biotechnology) experienced а -4.93% price change this week, while OVID (@Biotechnology) price change was +52.53% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +6.70%. For the same industry, the average monthly price growth was +18.85%, and the average quarterly price growth was +33.19%.

Reported Earning Dates

ALT is expected to report earnings on Aug 07, 2025.

OVID is expected to report earnings on Aug 18, 2025.

Industries' Descriptions

@Biotechnology (+6.70% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ALT($328M) has a higher market cap than OVID($43M). OVID YTD gains are higher at: -35.161 vs. ALT (-43.828). OVID has higher annual earnings (EBITDA): -56.4M vs. ALT (-90.75M). ALT has more cash in the bank: 150M vs. OVID (43M). ALT has less debt than OVID: ALT (1.59M) vs OVID (14.4M). OVID has higher revenues than ALT: OVID (548K) vs ALT (20K).
ALTOVIDALT / OVID
Capitalization328M43M763%
EBITDA-90.75M-56.4M161%
Gain YTD-43.828-35.161125%
P/E RatioN/AN/A-
Revenue20K548K4%
Total Cash150M43M349%
Total Debt1.59M14.4M11%
FUNDAMENTALS RATINGS
ALT vs OVID: Fundamental Ratings
ALT
OVID
OUTLOOK RATING
1..100
428
VALUATION
overvalued / fair valued / undervalued
1..100
97
Overvalued
36
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9797
PRICE GROWTH RATING
1..100
9192
P/E GROWTH RATING
1..100
10093
SEASONALITY SCORE
1..100
503

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

OVID's Valuation (36) in the Pharmaceuticals Major industry is somewhat better than the same rating for ALT (97) in the Miscellaneous Commercial Services industry. This means that OVID’s stock grew somewhat faster than ALT’s over the last 12 months.

OVID's Profit vs Risk Rating (100) in the Pharmaceuticals Major industry is in the same range as ALT (100) in the Miscellaneous Commercial Services industry. This means that OVID’s stock grew similarly to ALT’s over the last 12 months.

OVID's SMR Rating (97) in the Pharmaceuticals Major industry is in the same range as ALT (97) in the Miscellaneous Commercial Services industry. This means that OVID’s stock grew similarly to ALT’s over the last 12 months.

ALT's Price Growth Rating (91) in the Miscellaneous Commercial Services industry is in the same range as OVID (92) in the Pharmaceuticals Major industry. This means that ALT’s stock grew similarly to OVID’s over the last 12 months.

OVID's P/E Growth Rating (93) in the Pharmaceuticals Major industry is in the same range as ALT (100) in the Miscellaneous Commercial Services industry. This means that OVID’s stock grew similarly to ALT’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ALTOVID
RSI
ODDS (%)
Bullish Trend 2 days ago
78%
Bearish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
86%
Bearish Trend 2 days ago
90%
Momentum
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
83%
MACD
ODDS (%)
Bearish Trend 2 days ago
83%
Bullish Trend 2 days ago
77%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
89%
Bullish Trend 2 days ago
78%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
88%
Bullish Trend 2 days ago
77%
Advances
ODDS (%)
Bullish Trend 14 days ago
82%
Bullish Trend 2 days ago
74%
Declines
ODDS (%)
Bearish Trend 12 days ago
88%
Bearish Trend 8 days ago
88%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
88%
Bearish Trend 2 days ago
90%
Aroon
ODDS (%)
Bullish Trend 7 days ago
82%
Bullish Trend 2 days ago
83%
View a ticker or compare two or three
Interact to see
Advertisement
ALT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
OVID
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
LODE3.710.37
+11.08%
Comstock Inc.
UROY2.690.07
+2.67%
Uranium Royalty Corp
ESTA42.601.03
+2.48%
Establishment Labs Holdings
ISRG516.12-2.50
-0.48%
Intuitive Surgical
LPX86.07-1.34
-1.53%
Louisiana-Pacific Corp

ALT and

Correlation & Price change

A.I.dvisor indicates that over the last year, ALT has been loosely correlated with RVPH. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if ALT jumps, then RVPH could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ALT
1D Price
Change %
ALT100%
-0.74%
RVPH - ALT
51%
Loosely correlated
-0.95%
INDP - ALT
45%
Loosely correlated
-6.03%
VERA - ALT
39%
Loosely correlated
-1.13%
KROS - ALT
38%
Loosely correlated
+0.29%
OVID - ALT
36%
Loosely correlated
+10.07%
More

OVID and

Correlation & Price change

A.I.dvisor indicates that over the last year, OVID has been closely correlated with JBIO. These tickers have moved in lockstep 79% of the time. This A.I.-generated data suggests there is a high statistical probability that if OVID jumps, then JBIO could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To OVID
1D Price
Change %
OVID100%
+10.07%
JBIO - OVID
79%
Closely correlated
-8.24%
BEAM - OVID
48%
Loosely correlated
+1.35%
DNLI - OVID
47%
Loosely correlated
-1.21%
CRBU - OVID
45%
Loosely correlated
+0.98%
IPSC - OVID
45%
Loosely correlated
+0.84%
More